Sofia M. Possidento

Sofia M. Possidento

Auto-generated profile, based on publicly available information

Sofia M. Possidento

UCONN Health, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2025 in Circulation
Verified
Journal Article
Closed access
MTMoriah Gildart Turcotte
Moriah Gildart Turcotte
ASAnne-Maj Samuelsson
Anne-Maj Samuelsson
SPSofia M. Possidento
Sofia M. Possidento
JLJinliang Li
Jinliang Li
ZQZhuyun Qin
Zhuyun Qin
KDKimberly Dodge-Kafka
Kimberly Dodge-Kafka
BACKGROUND: β-Adrenergic receptors (βARs) are prototypical G protein–coupled receptors that regulate contractility in the normal heart and pathological remodeling in disease. Canonical βAR signaling originates at the plasma membrane, but functional βARs have been localized to intracellular membranes such as the endosome, sarcoplasmic reticulum, Golgi, and nuclear envelope. The functional significance of these intracellular receptors remains unclear, including whether they regulate cellular processes distinct from those regulated by plasma membrane receptors and whether they can be independently targeted for therapeutic benefit. METHODS: Live cell imaging of rat and human cardiomyocytes expressing novel compartment-specific modulators of βAR activity and fluorescent biosensors was used to study the compartment-specific βAR regulation of second messengers and to target enzyme activity. Compartmentalized signaling was compared with myocyte gene expression and hypertrophy. Adeno-associated virus gene delivery conferring gain and loss of perinuclear βAR activity was studied in wild-type mice and a mouse model of familial dilated cardiomyopathy. RESULTS: We demonstrate here that intracellular β 1 ARs present on Golgi membrane facing the outer nuclear membrane regulate a perinuclear cAMP compartment containing the A-kinase anchoring protein 6β signalosome, conferring selective regulation of perinuclear cAMP-dependent protein kinase activity independently of βARs at the plasma membrane or endosome. The A-kinase anchoring protein 6β compartment is shown to be of nanometer scale and dependent on local restriction of cAMP diffusion. In addition, perinuclear βARs are shown to be sufficient and necessary for activation of the Ca 2+ -dependent calcineurin–nuclear factor of activated T cells pathway and myocyte hypertrophy in vitro. Accordingly, adeno-associated virus 9–based delivery of an outer nuclear membrane–localized pepducin, which selectively activated perinuclear βARs in vitro, induced dilated cardiomyopathy in wild-type mice. Conversely, in vivo delivery of an outer nuclear membrane–localized nanobody, which selectively inhibited perinuclear βARs in vitro, improved cardiac function and inhibited pathological remodeling in a mouse model of familial dilated cardiomyopathy with established disease. CONCLUSIONS: These results demonstrate that β 1 ARs localized to Golgi membranes facing the outer nuclear membrane regulate A-kinase anchoring protein 6β signalosomes required for the induction of pathological cardiac remodeling, defining an intracellular nanocompartment. Proof of concept is provided for a novel therapeutic approach for familial dilated cardiomyopathy, with potential application to other forms of cardiovascular disease.

3 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MTMoriah Gildart Turcotte
Moriah Gildart Turcotte
ASAnne-Maj Samuelsson
Anne-Maj Samuelsson
SPSofia M. Possidento
Sofia M. Possidento
JLJinliang Li
Jinliang Li
ZQZhuyun Qin
Zhuyun Qin
KDKimberly Dodge-Kafka
Kimberly Dodge-Kafka
Summary: The β-adrenergic receptor is a prototypical G-protein coupled receptor that initiates signaling from the plasma membrane. However, active receptors have been detected within intracellular compartments. The functional significance of these intracellular receptors remains unclear, including whether they regulate distinct cellular processes or function independently of plasma membrane receptors. We show using live cell imaging of primary cardiomyocytes that β-adrenergic receptors localized to Golgi apparatus opposing the outer nuclear membrane are sufficient and necessary for the stimulation of cAMP and calcium signaling within a nanometer scale compartment independent of receptors at other sites. Using compartment-specific activators and inhibitors, we show Golgi β-adrenergic receptors associated with the scaffold protein AKAP6β and the outer nuclear membrane protein nesprin-1α are responsible for pathological gene transcription and the induction of cardiomyocyte hypertrophy. The functional significance of Golgi-localized receptors is demonstrated in mice models of cardiomyopathy, providing proof-of-concept for a compartment-specific therapeutic intervention in Dilated Cardiomyopathy.

28 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DTDarla L Tharp
Darla L Tharp
SPSofia M Possidento
Sofia M Possidento
JLJinliang Li
Jinliang Li
ABAbraham L Bayer
Abraham L Bayer
AAAmira R Amin
Amira R Amin
MKMichael S. Kapiloff
Michael S. Kapiloff
Background: Cardiometabolic heart failure with preserved ejection fraction (HFpEF) is associated with systemic and cardiac inflammation and diastolic dysfunction. A-kinase anchoring protein 6β (AKAP6β) is a scaffold protein located at the cardiomyocyte outer nuclear membrane that promotes pathological cardiac remodeling via the recruitment of multiple regulatory proteins including protein kinases. In mice, adeno-associated virus (AAV) mediated expression of a peptide based upon a kinase binding domain (KBD) within AKAP6β inhibited the development of heart failure due to chronic pressure overload. Whether KBD expression can also inhibit the development of cardiometabolic heart failure is unknown, and if so, the mechanism of KBD action in HFpEF has yet to be explored. Methods: The efficacy of a cardiotropic self-complementary AAV gene therapy that expresses the AKAP6β KBD peptide (AAV9sc.KBD) was tested in a female Ossabaw swine model of cardiometabolic syndrome and HFpEF. Single nucleus and bulk RNA sequencing of swine heart tissue and immunoprecipitation-mass spectrometry, live cell imaging, and biochemical assays using primary rat cardiomyocytes were employed to study KBD mechanism of action. Results: AAV9sc.KBD inhibited the development of diastolic dysfunction and heart failure in the Ossabaw model, without negatively impacting systolic function. The improvement in cardiac phenotype was associated with decreased T-cell myocardial infiltrates and partial reversal of pathological gene expression. An unbiased interactome study revealed that the KBD peptide binds Ca2+/calmodulin-dependent protein kinase II (CaMKII), identifying CaMKII as a new AKAP6β binding partner. Perinuclear CaMKII activity detected by live cell imaging required AKAP6β expression and was inhibited by KBD expression. In addition, the CaMKII substrate Inhibitor of NF-κB Kinase β (IKKβ) bound AKAP6β. IKK phosphorylation in the Ossabaw model and in myocytes was inhibited by KBD expression, and NF-κB nuclear translocation in myocytes was dependent upon AKAP6β-CaMKII protein complex formation. AAV9sc.KBD treatment inhibited cardiomyocyte NF-κB-dependent gene expression in the Ossabaw model. Conclusions: Regulated by perinuclear AKAP6β-CaMKII signalosomes, NF-κB pro-inflammatory gene expression in cardiomyocytes participates in a positive feedback loop with cardiac inflammation promoting HFpEF. Proof-of-concept is provided in a large animal model that gene therapy-based cardiomyocyte expression of the KBD peptide will prevent cardiac dysfunction in cardiometabolic syndrome.